Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise
by Society of Nuclear Medicine and Molecular ImagingTransversal (A), coronal (B), sagittal (C) nanoSPECT/CT images and maximum intensity projection (D) obtained 30 h after injection of pretargeted&nbs
Updated on: March 06,2024
12

Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise
by Society of Nuclear Medicine and Molecular ImagingTransversal (A), coronal (B), sagittal (C) nanoSPECT/CT images and maximum intensity projection (D) obtained 30 h after injection of pretargeted&nbs
Updated on:March 06,2024
12
